<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the influence of type 4 metabotropic <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> (mGlu4) receptors on ischemic brain damage using the permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model in mice and the endothelin-1 (Et-1) model of transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>Mice lacking mGlu4 receptors showed a 25% to 30% increase in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after MCAO as compared with <z:mp ids='MP_0002169'>wild-type</z:mp> littermates </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> mice, systemic injection of the selective mGlu4 receptor enhancer, N-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-7-(hydroxyimino)cyclopropa[b]chromen-1a-caboxamide (PHCCC; 10  mg/kg, subcutaneous, administered once 30  minutes before MCAO), reduced the extent of ischemic brain damage by 35% to 45% </plain></SENT>
<SENT sid="3" pm="."><plain>The drug was inactive in mGlu4 receptor knockout mice </plain></SENT>
<SENT sid="4" pm="."><plain>In the Et-1 model, PHCCC administered only once 20  minutes after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume to a larger extent in the caudate/putamen than in the cerebral cortex </plain></SENT>
<SENT sid="5" pm="."><plain>Ischemic rats treated with PHCCC showed a faster recovery of neuronal function, as shown by electrocorticographic recording and by a battery of specific tests, which assess sensorimotor deficits </plain></SENT>
<SENT sid="6" pm="."><plain>These data indicate that activation of mGlu4 receptors limit the development of brain damage after permanent or transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>These findings are promising because selective mGlu4 receptor enhancers are under clinical development for the treatment of <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> and other central <z:mp ids='MP_0008912'>nervous</z:mp> system disorders </plain></SENT>
</text></document>